NO20041758L - Crystalline sodium salt of telmiseartan and its use as angiotensin antagonist - Google Patents
Crystalline sodium salt of telmiseartan and its use as angiotensin antagonistInfo
- Publication number
- NO20041758L NO20041758L NO20041758A NO20041758A NO20041758L NO 20041758 L NO20041758 L NO 20041758L NO 20041758 A NO20041758 A NO 20041758A NO 20041758 A NO20041758 A NO 20041758A NO 20041758 L NO20041758 L NO 20041758L
- Authority
- NO
- Norway
- Prior art keywords
- telmiseartan
- sodium salt
- crystalline sodium
- angiotensin antagonist
- angiotensin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10153737A DE10153737A1 (en) | 2001-10-31 | 2001-10-31 | Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament |
PCT/EP2002/011394 WO2003037876A1 (en) | 2001-10-31 | 2002-10-11 | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20041758L true NO20041758L (en) | 2004-04-29 |
NO326465B1 NO326465B1 (en) | 2008-12-08 |
Family
ID=7704331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041758A NO326465B1 (en) | 2001-10-31 | 2004-04-29 | Crystalline sodium salt of Telmiseartan, process for the preparation of such, pharmaceutical formulations containing them and its use as a drug |
Country Status (35)
Country | Link |
---|---|
EP (1) | EP1442023B1 (en) |
JP (1) | JP5124076B2 (en) |
KR (1) | KR100929502B1 (en) |
CN (1) | CN100509789C (en) |
AR (1) | AR037148A1 (en) |
AT (1) | ATE370125T1 (en) |
AU (1) | AU2002338886B2 (en) |
BR (1) | BR0213568A (en) |
CA (1) | CA2463146C (en) |
CO (1) | CO5580785A2 (en) |
CY (1) | CY1107504T1 (en) |
DE (2) | DE10153737A1 (en) |
DK (1) | DK1442023T3 (en) |
EA (1) | EA007596B1 (en) |
EC (1) | ECSP045089A (en) |
ES (1) | ES2291505T3 (en) |
HK (1) | HK1073841A1 (en) |
HR (1) | HRPK20040372B3 (en) |
HU (1) | HUP0402391A3 (en) |
IL (2) | IL161165A0 (en) |
ME (1) | MEP43608A (en) |
MX (1) | MXPA04004013A (en) |
MY (1) | MY129741A (en) |
NO (1) | NO326465B1 (en) |
NZ (1) | NZ532716A (en) |
PE (1) | PE20030629A1 (en) |
PL (1) | PL211462B1 (en) |
PT (1) | PT1442023E (en) |
RS (1) | RS50879B (en) |
SA (1) | SA02230419B1 (en) |
SI (1) | SI1442023T1 (en) |
TW (2) | TWI341200B (en) |
UA (1) | UA82833C2 (en) |
UY (1) | UY27520A1 (en) |
WO (1) | WO2003037876A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10319450A1 (en) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical formulation of telmisartan sodium salt |
US9029363B2 (en) | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
CA2555294A1 (en) | 2004-02-11 | 2005-08-25 | Marina Yu Etinger | Candesartan cilexetil polymorphs |
CN1953973A (en) * | 2004-05-05 | 2007-04-25 | 特瓦制药工业有限公司 | Preparation of candesartan cilexetil in high purity |
EP1805146A4 (en) | 2004-10-18 | 2009-01-14 | Reddys Lab Ltd Dr | Process for preparing telmisartan |
CA2583694A1 (en) * | 2004-11-03 | 2006-05-11 | Teva Pharmaceutical Industries Ltd. | Amorphous and polymorphic forms of telmisartan sodium |
EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
EP2151450A1 (en) * | 2008-07-29 | 2010-02-10 | Sandoz AG | Method for processing microbiologically produced cyclic oligopeptides |
CA2761576C (en) | 2009-05-20 | 2017-08-22 | Boehringer Ingelheim Vetmedica Gmbh | Oral suspension comprising telmisartan |
EP2448575A2 (en) | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
WO2011002423A2 (en) | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
EP2632438A1 (en) | 2010-10-27 | 2013-09-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
CN103619556B (en) * | 2011-06-24 | 2016-12-07 | 本田技研工业株式会社 | Injection molding method and device thereof |
CR20190057A (en) | 2011-11-25 | 2019-04-23 | Adverio Pharma Gmbh | Method for producing substituted 5-fluoro-1h-pyrazolopyridines |
AU2015335950B2 (en) | 2014-10-21 | 2018-01-25 | Takeda Pharmaceutical Company Limited | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine |
KR101872726B1 (en) * | 2016-07-28 | 2018-06-29 | 주식회사 씨트리 | Telmisartan methanesulfonate and pharmaceutical composition comprising the same |
US10905676B2 (en) | 2017-07-07 | 2021-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats |
WO2020143793A1 (en) * | 2019-01-10 | 2020-07-16 | 石药集团中奇制药技术(石家庄)有限公司 | Salts of heterocyclic compound and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5594003A (en) * | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
SI9210098B (en) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoles, drugs with this compounds, and process for their preparation |
DK0883401T3 (en) * | 1996-02-29 | 2003-05-05 | Novartis Ag | AT1 receptor antagonist to stimulate apoptosis |
DE19901921C2 (en) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament |
-
2001
- 2001-10-31 DE DE10153737A patent/DE10153737A1/en not_active Ceased
-
2002
- 2002-10-11 HU HU0402391A patent/HUP0402391A3/en not_active Application Discontinuation
- 2002-10-11 SI SI200230594T patent/SI1442023T1/en unknown
- 2002-10-11 BR BR0213568-0A patent/BR0213568A/en active Pending
- 2002-10-11 CA CA2463146A patent/CA2463146C/en not_active Expired - Fee Related
- 2002-10-11 KR KR1020047006317A patent/KR100929502B1/en not_active IP Right Cessation
- 2002-10-11 ME MEP-436/08A patent/MEP43608A/en unknown
- 2002-10-11 CN CNB028216202A patent/CN100509789C/en not_active Expired - Fee Related
- 2002-10-11 AT AT02777305T patent/ATE370125T1/en active
- 2002-10-11 AU AU2002338886A patent/AU2002338886B2/en not_active Ceased
- 2002-10-11 ES ES02777305T patent/ES2291505T3/en not_active Expired - Lifetime
- 2002-10-11 DE DE50210719T patent/DE50210719D1/en not_active Expired - Lifetime
- 2002-10-11 EA EA200400479A patent/EA007596B1/en not_active IP Right Cessation
- 2002-10-11 PL PL367477A patent/PL211462B1/en unknown
- 2002-10-11 IL IL16116502A patent/IL161165A0/en unknown
- 2002-10-11 EP EP02777305A patent/EP1442023B1/en not_active Expired - Lifetime
- 2002-10-11 DK DK02777305T patent/DK1442023T3/en active
- 2002-10-11 NZ NZ532716A patent/NZ532716A/en not_active IP Right Cessation
- 2002-10-11 MX MXPA04004013A patent/MXPA04004013A/en active IP Right Grant
- 2002-10-11 WO PCT/EP2002/011394 patent/WO2003037876A1/en active IP Right Grant
- 2002-10-11 PT PT02777305T patent/PT1442023E/en unknown
- 2002-10-11 RS YUP-363/04A patent/RS50879B/en unknown
- 2002-10-11 JP JP2003540158A patent/JP5124076B2/en not_active Expired - Lifetime
- 2002-10-28 PE PE2002001061A patent/PE20030629A1/en not_active Application Discontinuation
- 2002-10-28 UY UY27520A patent/UY27520A1/en not_active Application Discontinuation
- 2002-10-29 MY MYPI20024051A patent/MY129741A/en unknown
- 2002-10-29 TW TW099114822A patent/TWI341200B/en not_active IP Right Cessation
- 2002-10-29 TW TW091132070A patent/TWI333419B/en not_active IP Right Cessation
- 2002-10-30 AR ARP020104113A patent/AR037148A1/en active Pending
- 2002-11-05 SA SA02230419A patent/SA02230419B1/en unknown
- 2002-11-10 UA UA20040503959A patent/UA82833C2/en unknown
-
2004
- 2004-03-30 IL IL161165A patent/IL161165A/en not_active IP Right Cessation
- 2004-04-26 HR HR20040372A patent/HRPK20040372B3/en not_active IP Right Cessation
- 2004-04-27 EC EC2004005089A patent/ECSP045089A/en unknown
- 2004-04-29 NO NO20041758A patent/NO326465B1/en not_active IP Right Cessation
- 2004-05-07 CO CO04042445A patent/CO5580785A2/en not_active Application Discontinuation
-
2005
- 2005-07-26 HK HK05106371.1A patent/HK1073841A1/en not_active IP Right Cessation
-
2007
- 2007-10-15 CY CY20071101332T patent/CY1107504T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20041758L (en) | Crystalline sodium salt of telmiseartan and its use as angiotensin antagonist | |
ATE258918T1 (en) | CRYSTAL FORM ALPHA OF PERINDOPRIL-TERT-BUTYLAMINE SALT | |
DK1478629T3 (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterial agents | |
IS2529B (en) | New spirotycyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
DE60303751D1 (en) | Real-time monitoring of formation fracture | |
NO20053569D0 (en) | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
IS7792A (en) | Hydantoin derivatives and their use as TACE inhibitors | |
NO20026010D0 (en) | Substituted quinazoline derivatives and their use as inhibitors | |
NO20043158L (en) | Substituted quinazoline derivatives as inhibitors of aurorakinases | |
DK1480962T3 (en) | 5-Phenylthiazole derivatives and their use as P1-3 kinase inhibitors | |
NO20005265L (en) | Substituted benzamides, their preparation and use as inhibitors of cystine proteases | |
PL376575A1 (en) | Substituted heterocyclic compounds and methods of use | |
FI20021262A0 (en) | Crystallization of sugars | |
EE04240B1 (en) | Potassium salt of (S) -omeprazole | |
NO20042719L (en) | Substituted 2-amino-cycloalkanecarboxamides and their use as protease inhibitors | |
ATE391502T1 (en) | CRYSTALLINE FORMS OF FLUVASTATIN SODIUM | |
DK1622612T3 (en) | Pharmaceutical formulation of the sodium salt of telmitarsan | |
PT1432685E (en) | CRYSTALLINE HYDRATES OF NICOTHINIC ACID AND BENZOYLENYLIDAN ANILIDA DERIVATIVES | |
AU2002338886A1 (en) | Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist | |
NO20040996L (en) | New Compounds and Compositions as Catepsin Inhibitors | |
IL164698A0 (en) | Attenuation of metapneumovirus | |
NO20041968L (en) | Use of cystationin | |
HUP0401641A3 (en) | Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors | |
FI20021531A (en) | Procedure for masonry | |
NO20044364L (en) | Hydroxycarbamimidoyl-2-hydroxy-benzenesulfonamide crystals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |